Background Antithyroid drugs remain an important treatment for hyperthyroidism due to Graves' disease (1). There are two main therapeutic protocols that are used; in the first scenario, antithyroid drugs are given for 12 to 18 months, and, if serum anti-TSH receptor antibody (TRAb) levels have normalized, the drug is discontinued and patients are monitored for recurrence. If antibodies persist, however, definitive treatment with radioiodine or surgery may be recommended (2,3), although continued antithyroid drug therapy is also reasonable in patients with well-controlled mild disease (2,3). In the second scenario, antithyroid drugs are given for as long as necessary, until TRAbs disappear. This could be for years or even for a lifetime (4,5). The aim of the current study was to describe long-term outcomes in 549 adult patients with Graves' disease treated with antithyroid drugs for >8 years and to relate remission and final outcomes to patterns of serum TRAb titers (6). Methods This retrospective study included 549 patients (mean age, 36-41 years) with untreated Graves' disease seen at the

No abstract

No abstract